In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Coronavirus disease 2019 (COVID-19) has encompassed the globe since it was first
observed just under 2 years ago. Although the disease is predominantly a respiratory …

Background New-onset atrial fibrillation (AF) during COVID-19 infection is associated with
worse cardiovascular outcomes and mortality, with new-onset AF being associated with …

Aims Electrophysiological (EP) operations that have traditionally involved long hospital
lengths of stay (LOS) are now being undertaken as day case procedures. The coronavirus …

Background and objectives: COVID-19 is associated with an aberrant inflammatory
response that may trigger new-onset cardiac arrhythmias. The aim of this study was to …

Background: Atrial fibrillation (AF) has been described as a common cardiovascular
manifestation in patients suffering from coronavirus disease 2019 (COVID-19) and has been …

The aim of the study was to investigate the role of chronic kidney disease (CKD) on in-
hospital mortality and on incident atrial fibrillation (AF) in patients infected with SARS-CoV-2 …

In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

Background Long-term consequences of COVID-19 are still partly known. Aim of the study
To derive a clinical score for risk prediction of long-term major cardiac adverse events …

(1) Background: Among the different cardiovascular (CV) manifestations of the coronavirus
disease 2019 (COVID-19), arrhythmia and atrial fibrillation (AF) in particular have recently …